loading page

Outcomes of High Dose Therapy and Autologous Haematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Analysis of Two Centres in Malaysia
  • +4
  • Nur Adila Anuar,
  • Kevin Wen Fei Tey,
  • Soo Chin Ng,
  • Alan Kee Hean Teh,
  • Mohd Haris Fadzillah Abdul Rahman,
  • bee chong,
  • Gin Gin Gan
Nur Adila Anuar
Universiti Malaya
Author Profile
Kevin Wen Fei Tey
Universiti Malaya
Author Profile
Soo Chin Ng
Subang Jaya Medical Centre
Author Profile
Alan Kee Hean Teh
Subang Jaya Medical Centre
Author Profile
Mohd Haris Fadzillah Abdul Rahman
Subang Jaya Medical Centre
Author Profile
bee chong
University of Malaya
Author Profile
Gin Gin Gan
University of Malaya
Author Profile

Abstract

There is scarce information available in regards to the survival outcome of non-Hodgkin lymphoma (NHL) in South East Asia regions. Reports on the outcome of High dose therapy followed by autologous haematopoietic stem cell transplantation (AHSCT) were mainly from developed countries. In this study, we present the outcome of NHL patients treated with AHSCT from year 1997 to 2016 in two urban hospitals in Malaysia. A total of 140 patients were identified, majority of whom had B cell lymphoma (54.3%). Majority of patients (89.3%) were in complete remission at AHSCT. The overall survival (OS) and event-free survival (EFS) at 3 years were 70.7% and 62.1% respectively. The transplant-related mortality was 3.4%.

Peer review status:ACCEPTED

09 Jun 2020Submitted to International Journal of Clinical Practice
12 Jun 2020Submission Checks Completed
12 Jun 2020Assigned to Editor
12 Jun 2020Reviewer(s) Assigned
20 Jul 2020Review(s) Completed, Editorial Evaluation Pending
02 Sep 20201st Revision Received
02 Sep 2020Submission Checks Completed
02 Sep 2020Assigned to Editor
02 Sep 2020Reviewer(s) Assigned
21 Sep 2020Review(s) Completed, Editorial Evaluation Pending
05 Oct 20202nd Revision Received
13 Oct 2020Submission Checks Completed
13 Oct 2020Assigned to Editor
13 Oct 2020Reviewer(s) Assigned
26 Oct 2020Review(s) Completed, Editorial Evaluation Pending
02 Nov 2020Editorial Decision: Accept